Articles les plus consultés

vendredi 13 juillet 2018

NINLARO® (ixazomib)维持治疗3期试验达到主要终点,显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义 | Business Wire

NINLARO® (ixazomib)维持治疗3期试验达到主要终点,显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义 | Business Wire: (美国商业资讯) -- 武田药品工业株式会社(TSE: 4502)今天宣布,3期TOURMALINE-MM3随机研究达到主要终点,显示NINLARO® (ixazomib)单药口服维持治疗组的无进展生存率(PFS)高于安慰剂组,差异有统计学意义。该试验评估NINLARO维持治疗对高剂量治疗(HDT)

Asia Pacific Cartilage Repair Market - Analysis from 2018-2024 - ResearchAndMarkets.com | Business Wire

Asia Pacific Cartilage Repair Market - Analysis from 2018-2024 - ResearchAndMarkets.com | Business Wire: The

CFN Media Exclusive Interview: Segra International's Cannabis Micropropagation Revolution

CFN Media Exclusive Interview: Segra International's Cannabis Micropropagation Revolution

ObsEva SA to start trading today on the SIX Swiss Exchange

ObsEva SA to start trading today on the SIX Swiss Exchange

Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer

Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer